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W
hen the British physician 
Patrick Manson incriminated 
mosquitoes as vectors of 
Wuchereria bancrofti in China 
in 1877, it was the first time 
that an insect had been associated with the 
active transmission of an agent of any human 
or animal disease. The minute filarial worms 
(microfilariae), were, however, first observed 
as blood parasites by another British physi-
cian, Timothy Lewis. A BMJ report in 1870 
records he had noticed microfilariae in the 
urine of patients.1 Manson had read Lewis’s 
work and postulated that the worms lived 
in the lymphatic system, and that like other 
similar parasites, the females produced lar-
vae viviparously. His curiosity about the fate 
of the microfilariae led to the discovery that 
they were transmitted by mosquitoes.
Lymphatic filariasis is a major cause of 
acute and chronic morbidity of humans in 
tropical and subtropical areas of Asia, Africa, 
the western Pacific, and some parts of the 
Americas. Over 20% of the world’s popula-
tion live in areas where they are at risk of 
infection with filarial parasites. An estimated 
120 million people are infected in at least 83 
endemic countries, with 91% of cases caused 
by W bancrofti and the remainder by Brugia 
malayi and B timori.2
Uniquely among vector borne infections, 
lymphatic filariasis can be transmitted by five 
genera of mosquito (Anopheles, Aedes, Culex, 
Mansonia, and Ochlerotatus). Human infection 
occurs when the third stage (L3) infective lar-
vae escape from the mosquito’s proboscis on 
to the skin and penetrate at the site of the 
bite. The larvae migrate to the lymphatic sys-
tem, where they mature into adult male and 
female worms. As Manson suspected, adult 
females release live microfilariae. Concen-
trations of microfilariae in the blood show 
periodic variation, peak-
ing at the time when the 
dominant vector mosquito 
bites.
Despite being one of 
the most debilitating 
conditions in the world, 
lymphatic filariasis has 
escaped the attention of 
mainstream health policy because it is not 
generally fatal and is restricted to tropical 
and subtropical countries, where it mainly 
affects poor people.3 Around 41 million 
people have visible symptoms, including 
lymphoedema, genital pathology (especially 
hydroceles), and elephantiasis.4 A further 76 
million have hidden infection, most often 
with microfilariae in their blood and hidden 
internal damage to their lymphatic and renal 
systems. About 44 million infected patients 
have recurrent infections and abnormalities 
of renal function.
Elimination programme
In 1997, the World Health Assembly 
passed a resolution urging member states 
to strengthen activities toward eliminating 
lymphatic filariasis by 2020. In 2000 the 
Global Alliance to Eliminate Lymphatic 
Filariasis was formed as a partnership to 
support national elimination programmes 
in endemic countries (www.filariasis.org) 
and WHO launched its Global Programme 
to Eliminate Lymphatic 
Filariasis .  Optimism 
that elimination can be 
achieved lies in the avail-
ability of safe, single dose, 
two drug treatment regi-
mens capable of reducing 
microfilaraemia to near 
zero levels for one year or 
more, along with remarkable improvement 
in techniques for diagnosing the infection. 
Vector control, which is logistically challeng-
ing, is desirable but not required to interrupt 
transmission. 
Nevertheless, the elimination campaign 
has its own challenges. Because lymphatic 
filariasis is not a fatal disease and does not 
threaten the developed world, there is less 
political motivation, finance, and engage-
ment of politicians than for diseases such 
as malaria, tuberculosis, polio, and AIDS. 
Greater financial commitment is crucial for 
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a global programme targeting over a billion 
people in 83 countries. A further challenge 
in implementation is to persuade people 
who have no symptoms to take the tablets.
Infected people need to take two drugs 
once a year for five to seven years to ensure 
interruption of transmission. In areas where 
lymphatic filariasis is coendemic with 
onchocerciasis (river blindness) the recom-
mended regimen is ivermectin 200 μg/kg 
plus albendazole 400 mg; elsewhere, the 
regimen should be diethylcarbamazine 6 
mg/kg plus albendazole 400 mg.5 The drugs 
are in tablet form and have a long shelf life 
at room temperature. 
The elimination programme aims to reach 
80% population coverage yearly, for at least 
five years in order to interrupt transmis-
sion of the parasite.6 GlaxoSmithKline has 
donated albendazole and Merck has donated 
ivermectin to treat both lymphatic filariasis 
and onchocerciasis, so drug cost is not a bar-
rier to participation. Awareness campaigns 
have used the safety, efficacy, and ancillary 
benefits of ivermectin and albendazole to 
improve compliance with mass drug distri-
bution. These drugs are also effective against 
soil transmitted helminths, which are a com-
mon problem that mothers in endemic areas 
know affects their children’s physical and 
intellectual development, and ivermectin is 
active against scabies and head lice.
In  de l iver ing 
treatment,  high 
priority is given to 
achieving full cover-
age of communities 
at risk, which may 
be states, provinces, 
districts, subdistricts, 
towns, or villages. 
Endemic commu-
nities are identified 
using rapid diagnos-
tic tools such as the 
immunochroma-
graphic card test.7 
Mass drug admin-
istration campaigns 
either deliver drugs 
to individual homes 
or dispense them 
from a fixed station that is easily accessible. 
Campaigns may be organised as a national 
day or over a few days. This approach is 
built around the use of community volun-
teers and strong social mobilisation and 
information, education, and communication 
strategies. Many national elimination pro-
grammes in Africa have adopted the com-
munity directed intervention strategy that 
was developed for ivermectin distribution to 
control onchocerciasis.6 In this model each 
community takes the lead role in planning, 
implementing, and assessing its local drug 
delivery strategy. It relies on community 
volunteers to distribute the drugs.
Manson’s discovery that W  bancrofti 
required a mosquito host to complete its 
life cycle suggested that the disease may 
be eliminated by controlling the vectors. 
Vector control is particularly attractive for 
lymphatic filariasis because, unlike malaria, 
the parasite does not multiply in the mos-
quito vector and only continuous exposure 
to bites of many infected mosquitoes main-
tains the infection in humans. Vector con-
trol alone, through indoor residual spraying, 
has interrupted transmission of the disease 
in Solomon Islands8 and Togo where Anoph-
eles mosquitoes are the only vectors.9 Recent 
studies have shown that insecticide treated 
bed nets are more effective than spraying in 
reducing transmis-
sion of  malaria,10 
and the same may 
be true for lym-
phatic filariasis. 
In communities 
where f i lariasis 
mosquitoes are a 
biting nuisance, the 
noticeable effect 
of vector control 
might help to gain 
community support 
for integrated con-
trol programmes 
that include drug 
treatment. 
Signs of success
In its first eight 
years the Global 
Programme to Elim-
inate Lymphatic 
Filariasis  delivered 
1.9 billion treatments to individuals living 
in 48 of the 83 endemic countries.11 Thirty 
two million disability adjusted life years have 
been averted since the programme was ini-
tiated in 2000. The 310 million treatments 
to the children and women of childbearing 
age have also significantly reduced intestinal 
helminths, onchocerciasis, lice, scabies, and 
other conditions, particularly anaemia.12 13
The programme has been successful 
because the disease mapping tools are sim-
ple and applicable in remote field settings. 
R.
UM
ES
H
 C
H
AN
DR
AN
, T
DR
, W
H
O
/S
PL
SI
N
CL
AI
R 
ST
AM
M
ER
S/
SP
L
larval stage of the parasitic worm Wucheria bancrofti
1472   BMJ | 20 June 2009 | VoluMe 338
Tropical Diseases
However, even with donated drugs, mass 
drug administration requires resources; char-
acteristically middle income countries have 
made the most progress. China became the 
first country declared to have eliminated the 
disease, followed by the Republic of Korea 
in March 2008.14 South East Asia has the 
highest burden of disease, with 859 million 
people at risk, but all nine endemic coun-
tries in the region have initiated mass drug 
administration programmes and four  (India, 
the Maldives, Sri Lanka and Thailand) have 
reached full geographic coverage. In 2007 
alone, 63.6% (546 million) of the target popu-
lation received treatment.14 
In Africa, where all 39 endemic countries 
are low income economies, only 15 were 
implementing mass drug administration in 
2007.14 Of the 382 million people at risk 
in the region only 47 million (12.3%) were 
treated. Resources for scaling up in poor 
countries is the key to achieving global elimi-
nation by 2020.
Recognising the need for economic 
empowerment and more resources in the 
poorest countries, the US increased its 
commitment to controlling neglected tropi-
cal diseases from $15m for 2008 to a total 
of $350m over the next five years. In July 
2008, the G8 leaders meeting in Japan called 
for efforts to control or eliminate neglected 
tropical diseases to be reinvigorated “by 
expanding health system coverage, alleviat-
ing poverty and social exclusion as well as 
promoting adequate integrated public health 
approaches, including through the mass 
administration of drugs.” In September 2008, 
the British government committed £50m to 
the control of neglected tropical diseases. In 
January this year, the Global Network for 
Neglected Tropical Diseases (www.global-
network.org) announced that it has received 
$34m from the Bill and Melinda Gates Foun-
dation to step up the global advocacy efforts 
to prevent and treat these diseases. If this 
momentum is maintained lymphatic filaria-
sis could be eliminated by 2020. Lymphatic 
filariasis is the core disease in integrated 
neglected disease programmes throughout 
the world and is the key platform given the 
availability of the donated drugs and their 
wide spectrum efficacy and safety.  
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Mr. T. R. Lewis had opportunities of making an examination of the 
urine of a patient in the General Calcutta Hospital under the care of Dr. 
Lyons, who had been suffering from the condition known as chylous 
urine for about a month, together with pain in the right testicle, and 
great emaciation, in spite of good food and a good appetite. As the 
colour closely resembled many rice-water stools, he carefully examined 
it, and was repaid in a way he had not anticipated. It was albuminous 
to the extent of about one-fourth of its bulk, slightly acid, with a specific 
gravity of 1.015. Ether caused a separation into two layers—a clear  urine-
like fluid containing oil-molecules, and a white homogeneous mass 
consisting of minutely molecular débris. Before the addition of reagents, 
the fluid under the microscope so closely resembled the condition 
of a cholera stool just described, as not to be distinguishable from 
it—yellowish-green cells, some hyaline, some granular, some protruding 
a tongue-like prominence, and others with the contained plasma 
puckered in various ways. A few of the larger corpuscles were seen to 
shift themselves (like amoebae) a distance fully their own diameter, the 
shape altering at the same time. At first he doubted that they really were 
blood-cells, as the extent of variation in size was considerable. The fluid 
very quickly gelatinised in the test-tube; indeed, it frequently does so 
in the patient’s bladder, giving rise to stoppages during micturition. He 
had not seen cholera discharges spontaneously gelatinise, although such 
a condition is said to occur. A portion of the coagulated mass (which, 
when stirred, closely resembled a lump of moist gluten) was teased on 
a slide with needles, and examined. It consisted of fibrillae studded 
with blood —granular cells, scarcely differing from those seen in the 
flakes of cholera discharge, except, perhaps, in being more universally 
granular. They seemed to present more of the character of pus-cells. In 
the midst of this fibro-albuminous matter, several embryos of a round worm 
were discovered every time the urine was examined. A careful sketch 
of a large one, after the addition of acetic acid, is given. In the course 
of a few minutes, when the sketch was nearly completed, a caudal bursa 
became visible under the influence of the acid. “When first seen,” says 
Mr. Lewis, “I thought they were some detached filaments of a fungus, 
judging from the hyaline structureless appearance presented. After a 
time, however, a few of them were observed to move very slowly, when 
all doubt as to their nature was at an end. It will not be surprising that 
the existence of these was not suspected, when we consider that fully 
two hundred of the larger size could pass abreast through a very small 
pin-hole, an orifice not exceding the fiftieth of an inch in diameter, as 
may be verified by a simple calculation. Perhaps this fact may help to 
throw some light on a very obscure disease, of which little is known 
beyond the symptoms, although frequently met with in some parts of 
the world; and, indeed, may perhaps account for its localisation to such 
places as the West Coast of Africa, where, I am told, it is by no means a 
rare malady. As the mature worm still retains a hold on its victim, being 
perhaps safely lodged in the kidney and I have not seen an embryo of 
this kind before, nor yet a drawing—I must leave to a more experienced 
helminthologist to decide to what species of nematode it belongs.”
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